Browse by author
Lookup NU author(s): Dr Jacqueline Stockley, Professor Craig Robson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Objective: To study the cellular effects of the anti-androgen bicalutamide on autophagy and its potential impact on response to androgen-ablation therapy (AAT) alone or combined with docetaxel chemotherapy in human prostate cancer LNCaP cells. Materials and Methods: LNCaP cells were treated with bicalutamide +/- docetaxel, and cellular effects were assayed: lipidated LC3 (a microtubule-associated protein) for autophagy and its trafficking to fuse with lysosome; flow cytometry using propidium iodide or caspase 3 for cell death; and sulforhodamine B assay for cell growth. Results: Bicalutamide treatment enhanced autophagy in LNCaP cells with increased level of autophagosome coupled with an altered cellular morphology reminiscent of neuroendocrine differentiation. Consistent with the literature on the interaction between androgen receptor activation and taxane chemotherapy, bicalutamide diminished docetaxel mediated cytotoxicity. Significantly, pharmacological inhibition of autophagy with 3-methyladenine significantly enhanced the efficacy cell kill mediated by AAT +/- docetaxel. Conclusion: Autophagy associated with bicalutamide treatment in LNCaP cells may have a pro-survival effect and strategy to modulate autophagy may have a potential therapeutic value.
Author(s): Bennett HL, Stockley J, Fleming JT, Mandal R, O'Prey J, Ryan KM, Robson CN, Leung HY
Publication type: Article
Publication status: Published
Journal: BJU International
Year: 2013
Volume: 111
Issue: 4
Pages: 672-682
Print publication date: 01/04/2013
Online publication date: 16/08/2012
ISSN (print): 1464-4096
ISSN (electronic): 1464-410X
Publisher: Wiley-Blackwell
URL: http://dx.doi.org/10.1111/j.1464-410X.2012.11409.x
DOI: 10.1111/j.1464-410X.2012.11409.x
Altmetrics provided by Altmetric
